Your browser is no longer supported. Please, upgrade your browser.
Puma Biotechnology, Inc.
Index- P/E- EPS (ttm)-1.43 Insider Own11.10% Shs Outstand39.70M Perf Week-5.36%
Market Cap419.45M Forward P/E- EPS next Y-1.02 Insider Trans-1.04% Shs Float34.41M Perf Month0.37%
Income-56.20M PEG- EPS next Q-0.28 Inst Own96.00% Short Float22.69% Perf Quarter10.11%
Sales235.50M P/S1.78 EPS this Y34.90% Inst Trans0.05% Short Ratio14.16 Perf Half Y5.07%
Book/sh-0.01 P/B- EPS next Y20.30% ROA-22.80% Target Price10.33 Perf Year21.19%
Cash/sh2.80 P/C3.85 EPS next 5Y- ROE-451.50% 52W Range5.50 - 15.00 Perf YTD5.07%
Dividend- P/FCF- EPS past 5Y16.20% ROI-56.50% 52W High-28.13% Beta1.16
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin83.60% 52W Low96.00% ATR0.67
Employees269 Current Ratio1.40 Sales Q/Q-9.90% Oper. Margin-18.70% RSI (14)48.54 Volatility5.69% 5.96%
OptionableYes Debt/Eq- EPS Q/Q-82.60% Profit Margin-23.90% Rel Volume0.57 Prev Close11.00
ShortableYes LT Debt/Eq- EarningsNov 05 AMC Payout- Avg Volume551.27K Price10.78
Recom3.30 SMA20-1.93% SMA502.51% SMA2005.14% Volume315,963 Change-2.00%
Jun-25-20Resumed BofA/Merrill Underperform $9
Oct-08-19Downgrade Goldman Neutral → Sell $24 → $8
May-10-19Downgrade Citigroup Buy → Neutral $24
May-10-19Downgrade Cantor Fitzgerald Overweight → Neutral $57 → $20
Jan-17-19Initiated Leerink Partners Mkt Perform $21
Jan-03-19Downgrade Guggenheim Buy → Neutral
Nov-19-18Upgrade Goldman Sell → Neutral
Nov-02-18Downgrade JP Morgan Neutral → Underweight
Nov-02-18Downgrade BofA/Merrill Buy → Underperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $75
Sep-17-18Initiated Goldman Sell $42
May-11-18Reiterated Stifel Buy $95 → $87
Nov-10-17Reiterated RBC Capital Mkts Sector Perform $92 → $108
Nov-10-17Reiterated Citigroup Buy $156 → $164
Oct-02-17Reiterated Stifel Buy $110 → $130
Sep-11-17Reiterated Credit Suisse Outperform $118 → $136
Jul-10-17Resumed Leerink Partners Outperform $115
Jun-06-17Reiterated RBC Capital Mkts Sector Perform $60 → $88
May-25-17Reiterated RBC Capital Mkts Sector Perform $40 → $60
Mar-02-17Reiterated RBC Capital Mkts Sector Perform $48 → $17
Jan-15-21 08:03AM  
Jan-05-21 04:15PM  
Jan-04-21 04:15PM  
Dec-16-20 05:22PM  
Dec-11-20 05:00PM  
Dec-09-20 07:31PM  
Dec-05-20 11:32AM  
Dec-02-20 08:30AM  
Nov-17-20 04:15PM  
Nov-09-20 12:11PM  
Nov-06-20 04:30PM  
Nov-05-20 05:35PM  
Nov-03-20 04:15PM  
Oct-29-20 12:35PM  
Oct-22-20 04:15PM  
Oct-14-20 05:44PM  
Oct-12-20 12:27PM  
Oct-05-20 04:15PM  
Oct-02-20 05:05PM  
Sep-08-20 04:15PM  
Sep-05-20 11:31AM  
Sep-03-20 05:30PM  
Aug-19-20 04:10PM  
Aug-11-20 02:06PM  
Aug-10-20 05:15PM  
Aug-07-20 01:22PM  
Aug-06-20 06:35PM  
Jul-30-20 12:33PM  
Jul-27-20 08:45AM  
Jul-23-20 04:15PM  
Jul-17-20 07:41AM  
Jul-16-20 04:30PM  
Jul-09-20 05:30PM  
Jul-08-20 07:00PM  
Jun-22-20 12:19PM  
Jun-19-20 08:15AM  
Jun-12-20 08:48PM  
Jun-06-20 11:31AM  
Jun-02-20 05:15PM  
May-26-20 11:18AM  
May-14-20 09:42AM  
May-13-20 09:18AM  
May-11-20 12:01PM  
May-09-20 02:31PM  
May-08-20 04:45PM  
May-07-20 06:45PM  
May-06-20 04:20PM  
Apr-30-20 04:15PM  
Apr-21-20 05:55PM  
Apr-08-20 10:28AM  
Apr-03-20 05:30PM  
Apr-02-20 08:00AM  
Mar-25-20 05:01PM  
Mar-24-20 01:00PM  
Mar-21-20 11:30AM  
Mar-09-20 10:09AM  
Mar-05-20 05:15PM  
Feb-28-20 08:15AM  
Feb-26-20 08:03AM  
Feb-23-20 09:43AM  
Feb-21-20 06:07PM  
Feb-20-20 04:07PM  
Feb-19-20 04:51PM  
Feb-07-20 04:55PM  
Jan-21-20 09:26AM  
Jan-20-20 10:48AM  
Jan-13-20 07:30AM  
Jan-09-20 05:15PM  
Jan-07-20 04:15PM  
Dec-16-19 05:55PM  
Dec-13-19 06:00PM  
Dec-12-19 04:57PM  
Dec-11-19 06:03PM  
Dec-06-19 11:31AM  
Dec-03-19 08:59AM  
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUNT DOUGLAS MSee RemarksJan 04Sale10.236,46366,14550,295Jan 06 06:42 PM
BRYCE RICHARD PAULSEE REMARKSJan 04Sale10.236,54867,01670,079Jan 06 06:36 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 04Sale10.2218,235186,3804,284,258Jan 06 08:05 PM
NOUGUES MAXIMO FChief Financial OfficerJan 04Sale10.222,14521,93013,415Jan 06 06:48 PM
BRYCE RICHARD PAULSEE REMARKSDec 02Sale11.65921,07276,627Dec 04 04:34 PM
AUERBACH ALAN HPRESIDENT AND CEODec 02Sale11.663554,1384,302,493Dec 04 04:32 PM
BRYCE RICHARD PAULSEE REMARKSNov 02Sale7.819775876,719Nov 03 07:28 PM
AUERBACH ALAN HPRESIDENT AND CEONov 02Sale7.823712,8994,302,848Nov 03 07:25 PM
AUERBACH ALAN HPRESIDENT AND CEOOct 02Sale10.133503,5454,303,219Oct 05 06:13 PM
BRYCE RICHARD PAULSEE REMARKSOct 02Sale10.149192376,816Oct 05 05:25 PM
MOYES JAY MDirectorSep 16Sale10.009,70397,03031,570Sep 17 05:18 PM
BRYCE RICHARD PAULSEE REMARKSSep 02Sale9.779087976,907Sep 03 05:27 PM
AUERBACH ALAN HPRESIDENT AND CEOSep 02Sale9.783473,3934,303,569Sep 03 05:25 PM
BRYCE RICHARD PAULSEE REMARKSAug 03Sale10.808692976,997Aug 05 04:35 PM
AUERBACH ALAN HPRESIDENT AND CEOAug 03Sale10.793303,5614,303,916Aug 05 04:33 PM
HUNT DOUGLAS MSee RemarksJul 02Sale10.695726,11256,758Jul 06 08:37 PM
BRYCE RICHARD PAULSEE REMARKSJul 02Sale10.676607,04077,083Jul 06 08:02 PM
AUERBACH ALAN HPRESIDENT AND CEOJul 02Sale10.662,60727,8034,304,246Jul 06 07:36 PM
MOYES JAY MDirectorJun 16Sale9.509,72092,34041,273Jun 17 07:47 PM
WILSON TROY EDWARDDirectorJun 11Sale9.9725,245251,69326,098Jun 15 04:36 PM
Senderowicz AdrianDirectorJun 11Sale9.8910,00098,87840,993Jun 15 04:34 PM
BRYCE RICHARD PAULSEE REMARKSJun 02Sale10.668994977,743Jun 03 05:26 PM
AUERBACH ALAN HPRESIDENT AND CEOJun 02Sale10.713423,6624,306,853Jun 04 04:36 PM
BRYCE RICHARD PAULSEE REMARKSMay 04Sale9.628985677,832May 06 04:55 PM
AUERBACH ALAN HPRESIDENT AND CEOMay 04Sale9.703393,2894,307,195May 06 04:53 PM
BRYCE RICHARD PAULSEE REMARKSApr 02Sale7.379167177,921Apr 03 04:42 PM
AUERBACH ALAN HPRESIDENT AND CEOApr 02Sale7.393472,5634,307,534Apr 03 04:39 PM
AUERBACH ALAN HPRESIDENT AND CEOMar 02Sale10.023723,7264,307,881Mar 03 04:38 PM
BRYCE RICHARD PAULSEE REMARKSMar 02Sale10.029696278,012Mar 03 04:41 PM
HUNT DOUGLAS MSee RemarksFeb 27Sale10.251,72817,71752,830Mar 02 04:35 PM
BRYCE RICHARD PAULSEE REMARKSFeb 03Sale8.0210584234,834Feb 04 05:41 PM
AUERBACH ALAN HPRESIDENT AND CEOFeb 03Sale8.013312,6534,180,700Feb 04 05:37 PM